Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • May 23

    Regeneron Announces Upcoming Investor Conference Presentation
  • May 16

    Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma


  • 2019 Annual Meeting of Shareholders
    Jun 14
    10:30 AM EDT
    Jun 14, 2019 | 10:30 AM EDT

  • Goldman Sachs Global Healthcare Conference
    Jun 11
    9:20 AM PDT
    Jun 11, 2019 | 9:20 AM PDT